MARAVAI LIFESCIENCES HLDGS-A (MRVI) Stock Overview
USA - NASDAQ:MRVI - US56600D1072 - Common Stock
MRVI Key Statistics, Chart & Performance
The current stock price of MRVI is 3.23 USD. In the past month the price increased by 12.54%. In the past year, price decreased by -56.7%.
MRVI Latest News, Press Relases and Analysis
MRVI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 24.89 | 210.57B | ||
| DHR | DANAHER CORP | 28.13 | 155.31B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 143.51 | 46.81B | ||
| A | AGILENT TECHNOLOGIES INC | 26.76 | 41.35B | ||
| IQV | IQVIA HOLDINGS INC | 19.02 | 37.08B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.34 | 28.93B | ||
| WAT | WATERS CORP | 28.29 | 20.59B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 40.1 | 20.39B | ||
| MEDP | MEDPACE HOLDINGS INC | 40.6 | 16.31B | ||
| TEM | TEMPUS AI INC | N/A | 15.04B | ||
| ILMN | ILLUMINA INC | 23.51 | 15.03B | ||
| ICLR | ICON PLC | 13.47 | 13.82B |
Related stock screener links
About MRVI
Company Profile
Maravai Lifesciences Holdings, Inc. is a life sciences company. The company is headquartered in San Diego, California and currently employs 560 full-time employees. The company went IPO on 2020-11-20. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. The company serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
Company Info
MARAVAI LIFESCIENCES HLDGS-A
10770 Wateridge Circle Suite 200, Suite 200
San Diego CALIFORNIA 92121 US
CEO: Carl Hull
Employees: 580
Phone: 18585460004
MARAVAI LIFESCIENCES HLDGS-A / MRVI FAQ
What does MARAVAI LIFESCIENCES HLDGS-A do?
Maravai Lifesciences Holdings, Inc. is a life sciences company. The company is headquartered in San Diego, California and currently employs 560 full-time employees. The company went IPO on 2020-11-20. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. The company serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
What is the stock price of MARAVAI LIFESCIENCES HLDGS-A today?
The current stock price of MRVI is 3.23 USD. The price decreased by -3.29% in the last trading session.
What is the dividend status of MARAVAI LIFESCIENCES HLDGS-A?
MRVI does not pay a dividend.
How is the ChartMill rating for MARAVAI LIFESCIENCES HLDGS-A?
MRVI has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for MARAVAI LIFESCIENCES HLDGS-A?
MARAVAI LIFESCIENCES HLDGS-A (MRVI) has a market capitalization of 824.81M USD. This makes MRVI a Small Cap stock.
Can you provide the upcoming earnings date for MARAVAI LIFESCIENCES HLDGS-A?
MARAVAI LIFESCIENCES HLDGS-A (MRVI) will report earnings on 2025-11-06, after the market close.
MRVI Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to MRVI. When comparing the yearly performance of all stocks, MRVI is a bad performer in the overall market: 79% of all stocks are doing better.
MRVI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MRVI. While MRVI seems to be doing ok healthwise, there are quite some concerns on its profitability.
MRVI Financial Highlights
Over the last trailing twelve months MRVI reported a non-GAAP Earnings per Share(EPS) of -0.24. The EPS decreased by -1100% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.71% | ||
| ROE | -73.24% | ||
| Debt/Equity | 1.2 |
MRVI Forecast & Estimates
17 analysts have analysed MRVI and the average price target is 4.08 USD. This implies a price increase of 26.32% is expected in the next year compared to the current price of 3.23.
For the next year, analysts expect an EPS growth of -220.75% and a revenue growth -26.2% for MRVI